HC Wainwright & Co. Maintains Buy on Cogent Biosciences, Raises Price Target to $56
Benzinga Newsdesk 14 hours ago
Analyst RatingsNewsPrice Target
HC Wainwright & Co. analyst Robert Burns maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $55 to $56.
HC Wainwright & Co. analyst Robert Burns maintains Cogent Biosciences (NASDAQ:COGT) with a Buy and raises the price target from $55 to $56.